BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Raptor Pharmaceutical buy provides broader 'Horizon' in rare disease space
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Raptor Pharmaceutical buy provides broader 'Horizon' in rare disease space
Sep. 13, 2016
By
Marie Powers
No Comments
Horizon plc is picking up Raptor Pharmaceutical Corp. in an all-cash deal, acquiring outstanding shares of the Novato, Calif.-based company for $9 apiece to value the transaction at approximately $800 million.
BioWorld